Original Article

Evaluation of Piperacillin/Tazobactam Use and Resistance Pattern in a Teaching Hospital, Northwest Iran

Abstract

Background: Inappropriate use of broad-spectrum antibiotics has contributed to the emergence of resistant microorganisms, increased treatment costs, morbidity and mortality, drug toxicity, and prolonged hospitalization period. Determining the epidemiology of antibiotic resistance in various hospital wards allows for more precise drug selection in the hospital setting. This study evaluated the use and resistance pattern of a broad-spectrum antibiotic, Piperacillin/tazobactam, in Imam Khomeini, a referral teaching hospital in Urmia, Iran. Methods: All hospitalized patients who were treated with Piperacillin\Tazobactam from January to August 2018 were included. Demographic (age, sex, weight, comorbidities) and clinical data (Indication, dosing, duration of the treatment, susceptibility test, creatinine clearance, need for dose adjustment, clinical outcome, and mortality) of the patients were collected, and the compliance of piperacillin\tazobactam administration and its resistance pattern was assessed according to Lexi-comp- 2019 recommendations. Results: Among 177 patients, 88.7% received piperacillin\tazobactam without any appropriate susceptibility tests. The piperacillin disk was used in only 33.3% of the culture-positive cases in our research, with 70% resistance. Acinetobacter was the most common bacteria found in our culture-positive samples. The average duration of piperacillin\tazobactam treatment was 8.52 ± 5.84 days. Indications in 8.5%, doses in 18.5%, prescription period in 19.7%, and dose intervals in 31.4% of the cases were inappropriate. Piperacillin\tazobactam was mainly administered for pneumonia (34.5%) Conclusion: This study showed an injudicious use of Piperacillin/tazobactam in our hospital, evidenced by the significant number of inappropriate doses, intervals, and treatment duration. Decision-making based on susceptibility tests using appropriate and accurate methods, close monitoring of the patients' clinical status, including creatinine clearance, and antimicrobial stewardship programs may optimize the rational administration of broad-spectrum antimicrobials and avoid the emergence of bacterial resistance.

1. Korai U, Naqvi GR, Zafar F, et al. Drug utilization evaluation of Piperacillin/Tazobactam: A prospective and cross sectional investigation in tertiary care setup. Pak J Pharm Sci 2019;32(4):1861–7.
2. Erbay A, Çolpan A, Bodur H, Çevik MA, Samore MH, Ergönül Ö. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents 2003;21(4):308-12.
3. Shoaei SD, Bagherzadeh A, Haghighi M, Shabani M. Vancomycin and five broad-spectrum antibiotic utilization evaluation in an educational medical center in one year. J Pharm Care 2014;2(4):154–61.
4. Ayinalem G, Gelaw B, Belay A, Linjesa J. Drug use evaluation of ceftriaxone in medical ward of Dessie Referral Hospital, North East Ethiopia. Int J Basic Clin Pharmacol 2013;2(6):711-717.
5. Slama TG, Amin A, Brunton SA, et al. A clinician’s guide to the appropriate and accurate use of antibiotics: The Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. Am J Med 2005;118 Suppl 7A:1S-6S.
6. Raveh D, Muallem-Zilcha E, Greenberg A, Wiener-Well Y, Schlesinger Y, Yinnon AM. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: Cefepime, piperacillin-tazobactam and meropenem. QJM 2006;99(6):397-406.
7. Young M, Plosker GL. Piperacillin/tazobactam in moderate to severe bacterial infections. Disease Management and Health Outcomes 2002;10:195-199.
8. Lexicomp. Piperacillin and tazobactam : Drug information Brand Names : US Pharmacologic Category Dosing : Adult. In: UpToDate. 2019.
9. Khan FY, Elhiday A, Khudair IF, et al. Evaluation of the use of piperacillin/tazobactam (Tazocin®) at Hamad General Hospital, Qatar: Are there unjustified prescriptions? Infect Drug Resist 2012;5:17-21.
10. Beahm NP, Fryters SR. Prospective audit and feedback of piperacillin-tazobactam use in a large urban tertiary care hospital. J Assoc Med Microbiol Infect Dis Canada 2018;4(30:217-221.
11. Korai U, Naqvi GR, Zafar F, et al. Drug utilization evaluation of Piperacillin/Tazobactam: A prospective and cross sectional investigation in tertiary care setup. Pak J Pharm Sci 2019;32(4(Supplementary)):1861-1867.
12. Saleh P, Hamishekar H, Naeimzadeh F, Mikaili S, Osquee HO, Rezaee H. Drug Utilization Evaluation of Two Broad-Spectrum Antimicrobials: Cefepime and Piperacillin/Tazobactam in a Teaching Hospital in Tabriz, Iran. J Pharm Care 2019;7(1–2):21–5.
13. Ismail M, Iqbal Z, Hammad M, Ahsan S, et al. Drug utilization evaluation of Piperacillin/Tazobactam in a tertiary care teaching hospital. HealthMED 2010;4(4):1044.
14. Raveh D, Muallem-Zilcha E, Greenberg A, Wiener-Well Y, Schlesinger Y, Yinnon AM. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. J Assoc Physicians 2006;99(6):397–406.
15. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014;34(7):670-6.
Files
IssueVol 10, No 2 (Spring 2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v10i2.9973
Keywords
Antibiotic Drug Utilization Evaluation Microbial Resistance Piperacillin – Tazobactam

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Shiva A, Gharehghomi S, Hatamkhani S. Evaluation of Piperacillin/Tazobactam Use and Resistance Pattern in a Teaching Hospital, Northwest Iran. J Pharm Care. 2022;10(2):48-54.